High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir plus Dasabuvir Plus Ribavirin

被引：0

作者：

Mantry, Parvez S. ^{[1
]}

Kwo, Paul Y. ^{[2
]}

Coakley, Eoin ^{[3
]}

Te, Helen S. ^{[4
]}

Vargas, Hugo E. ^{[5
]}

Brown, Robert S. ^{[6
]}

Gordon, Fredric D. ^{[7
]}

Levitsky, Josh ^{[8
]}

Terrault, Norah ^{[9
]}

Burton, James R. ^{[10
]}

Xie, Wangang ^{[3
]}

Setze, Carolyn ^{[3
]}

Badri, Prajakta ^{[3
]}

Vilchez, Regis A. ^{[3
]}

Forns, Xavier ^{[11
,12
]}

机构：

[1] Liver Inst Methodist Dallas, Dallas, TX USA

[2] Indiana Univ, Indianapolis, IN 46204 USA

[3] AbbVie Inc, N Chicago, IL USA

[4] Univ Chicago Med, Chicago, IL USA

[5] Mayo Clin, Mayo Clinic, AZ 5 USA

[6] Columbia Univ, Ctr Liver Dis & Transplantat, Med Ctr, New York, NY USA

[7] Lahey Hosp & Med Ctr, Burlington, MA USA

[8] Northwestern Univ, Comprehens Transplant Ctr, Chicago, IL 60611 USA

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

[10] Univ Colorado, Denver, CO 80202 USA

[11] IDIBAPS, Hosp Clin, Liver Unit, Barcelona, Spain

[12] CIBEREHD, Barcelona, Spain

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

198

引用

页码：298A / 299A

页数：2

共 50 条

[1] Population Pharmacokinetics of ABT-450, Ombitasvir, Dasabuvir, Ritonavir and Ribavirin in Subjects with HCV Genotype 1 Infection
Mensing, Sven
Polepally, Akshanth
Koenig, Denise
Khatri, Amit
Liu, Wei
Podsadecki, Thomas
Awni, Walid
Menon, Rajeev
Dutta, Sandeep
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S42 - S43
[2] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Andreone, Pietro
Colombo, Massimo G.
Enejosa, Jeffrey V.
Koksal, Iftihar
Ferenci, Peter
Maieron, Andreas
Muellhaupt, Beat
Horsmans, Yves
Weiland, Ola
Reesink, Henk W.
Rodrigues, Lino, Jr.
Hu, Yiran B.
Podsadecki, Thomas
Bernstein, Barry
GASTROENTEROLOGY, 2014, 147 (02) : 359 - +
[3] M12-999:ABT-450/r/ABT-267+ABT-333+Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection
Mantry, P.
Kwo, P.
Coakley, E.
Te, H.
Vargas, H.
Brown, R., Jr.
Gordon, F.
Levitsky, J.
Terrault, N.
Burton, J., Jr.
Xie, W.
Setze, C.
Badri, P.
Vilchez, R.
Forns, X.
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 3 - 4
[4] EXPOSURE-RESPONSE ANALYSES FOR EFFICACY (SVR12) FOR THE DIRECT ACTING ANTIVIRAL REGIMEN OF ABT-450/R, OMBITASVIR WITH DASABUVIR plus /- RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION
Khatri, A.
Mensing, S.
Podsadecki, T.
Awni, W.
Menon, R.
Dutta, S.
JOURNAL OF HEPATOLOGY, 2015, 62 : S682 - S682
[5] M12-999:ABT-450/r/ABT-267+ABT-333+Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection.
Mantry, P.
Kwo, P.
Coakley, E.
Te, H.
Vargas, H.
Brown, R., Jr.
Gordon, F.
Levitsky, J.
Terrault, N.
Burton, J., Jr.
Xie, W.
Setze, C.
Badri, P.
Vilchez, R.
Forns, X.
TRANSPLANTATION, 2014, 98 : 3 - 4
[6] Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
Lawitz, Eric
Sullivan, Greg
Rodriguez-Torres, Maribel
Bennett, Michael
Poordad, Fred
Kapoor, Mudra
Badri, Prajakta
Campbell, Andrew
Rodrigues, Lino, Jr.
Hu, Yiran
Pilot-Matias, Tami
Vilchez, Regis A.
JOURNAL OF INFECTION, 2015, 70 (02) : 197 - 205
[7] Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and Phase 3 Trials
Fried, Michael W.
Di Bisceglie, Adrian M.
Vierling, John M.
Gane, Edward J.
Nevens, Frederik
Strasser, Simone I.
Weiland, Ola
Rugina, Sorin
Lovell, Sandra S.
Da Silva-Tillmann, Barbara
Shulman, Nancy
Tsai, Naoky
Nelson, David R.
HEPATOLOGY, 2014, 60 : 1145A - 1145A
[8] Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients
Bernstein, David
Tsai, Naoky
Hassanein, Tarek
Rodriguez-Perez, Federico
Romero-Gomez, Manuel
Marinho, Rui
Planas Vila, Ramon
Colombo, Massimo
Lovell, Sandra
Enejosa, Jeffrey
Luo, Yan
Cohen, Daniel
Pedrosa, Marcos
Reddy, K. Rajender
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S133 - S134
[9] Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From PEARL II, PEARL III, and PEARL IV
Lalezari, Jacob P.
Pruitt, Ronald
Luo, Yan
Aspinall, Richard J.
Gaeta, Giovanni B.
Olszok, Iwona
King, William
Gurel, Selim
Hu, Yiran
Enejosa, Jeffrey
Cohen, Daniel E.
Shulman, Nancy
Luketic, Velimir A.
HEPATOLOGY, 2014, 60 : 1151A - 1151A
[10] Sustained virologic response rates in HCV genotype 1-infected patients treated for 8 weeks with ombitasvir/paritaprevir/r and dasabuvir with ribavirin
Zeuzem, S.
Gane, E.
Agarwal, K.
Cohen, D.
Xie, W.
Dylla, D.
Tatsch, F.
Foster, G.
JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 27 - 27

← 1 2 3 4 5 →